The presentation of multiple abstracts on Epcoritamab at a significant medical congress such as the European Hematology Association Congress is likely to be viewed positively by investors and analysts. It indicates progress in Genmab's research and development efforts and could potentially lead to breakthroughs in treatment options for hematological malignancies. Positive data presented at the congress could significantly enhance investor confidence in Genmab's pipeline and future revenue potential, thus potentially leading to a short-term positive impact on GMAB's stock price.